Liquidia's Chairman Sold Company Shares Worth $2.5 Million. Should Investors Avoid the Stock?
Why it matters: Liquidia's Chairman sold $2.53 million in shares, but retained over two million, signaling continued confidence in LQDA's future.
- Stephen M. Bloch, Chairman of Liquidia's Board, indirectly sold 70,234 shares valued at $2.53 million, according to an SEC Form 4 filing.
- The sale represents only 3.02% of Bloch’s total reported holdings and did not impact his direct ownership, with all shares sold attributed to indirect holdings via Canaan VIII, L.P.
- Analysts interpret the transaction as routine portfolio rebalancing or liquidity management, noting it's Bloch's only open-market sale in the relevant historical window, suggesting no change in long-term conviction.
- Liquidia Corporation (LQDA) saw its stock on an upswing, hitting a 52-week high of $46.67 in February, reflecting strong business performance.
- The company closed 2025 with $158.3 million in sales, a substantial increase from $14 million in 2024, and achieved net income of $14.6 million in Q4, marking its second consecutive profitable quarter.
- CEO Roger Jeffs lauded Liquidia's YUTREPIA product as "one of the top specialty drug launches over the past five years," contributing to the company's financial success.
Liquidia Corporation's (LQDA) Chairman, Stephen M. Bloch, indirectly sold 70,234 shares worth $2.53 million, representing a modest 3.02% of his total holdings, which analysts suggest is likely for portfolio rebalancing rather than a lack of confidence. This sale occurred as Liquidia's stock was performing strongly, with the company achieving significant revenue growth to $158.3 million in 2025 and two consecutive profitable quarters, driven by the success of its YUTREPIA product.
